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Abstract
Physiological plasticity enables homeostasis to be maintained in biological systems, but when such allostasis fails, then disease
can develop. In a new population-based study by Rolandsson et al (https://doi.org/10.1007/s00125-019-05016-3), autoimmunity,
defined by an immunogenotype, predicted adult-onset non-insulin requiring diabetes. Type 1 diabetes is no longer viewed as a
disease confined to children, with a significant proportion, maybe the majority, presenting in adulthood. Such cases masquerade
as type 2 diabetes and their identification has clinical utility. Nevertheless, in this study, autoimmunity had a limited effect on the
overall risk of adults developing diabetes.
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EPIC European Prospective Investigation into Cancer and
Nutrition
GADA GAD65 autoantibodies
GRS Genetic risk score
HUNT Nord-Trøndelag Health Study
LADA Latent autoimmune diabetes in adults
Epidemics in the 19th century were, in the main, due to infec-
tious diseases; diabetes was different. In 1888 Etienne
Lancereaux, a French physician, believed that individuals
with diabetes were either thin (‘maigre’) or fat (‘gras’) [1].
More precisely, the latter were invariably rich and fat. Adult-
onset diabetes was considered a disease of civilisation,
secondary to poor digestion and bad nerves, but a homoge-
neous disease, nonetheless, with a homogeneous outcome. In
contrast people with ‘diabete maigre’ were invariably thin,
young, desperately ill and, within a year, dead. The introduc-
tion of insulin in 1921 commuted the death sentence to a life
sentence but emphasised that self-evident distinction between
the insulin-dependent form of diabetes and everything else,
then called non-insulin-dependent diabetes, now type 2
diabetes. Ascribing the modern global epidemic of adult-
onset diabetes to a maladaptation to civilisation did not, until
recently, alter the perspective that the disease could be lumped
under one umbrella with a common pathogenesis and uniform
therapeutic pathway.
Diabetes as a binary disease
That binary perspective of diabetes changed as we engaged
with maturity onset diabetes of the young (MODY) and adult-
onset autoimmune diabetes, also called latent autoimmune
diabetes in adults (LADA) [2]. Awareness that the patient in
front of you, young or old, lean or fat, could have different
forms of diabetes, has pushed physicians away from simple
clinical assessment into the realm of precision medicine. For
the patient with adult-onset diabetes, three features, aside from
demographics, have provided traction in dissecting the nature
of this disease process: genetics, including genetic risk scores
(GRS); immunology, in the form of diabetes autoantibodies,
including autoantibodies to GAD65 (GADA), and serum C-
peptide as a proxy for insulin secretion (Fig. 1) [2, 3].
GADA and GRS predicts adult-onset diabetes
In this issue ofDiabetologia, Rolandsson and colleagues have
leveraged two of these three markers, i.e. GADA and GRS, in
European Prospective Investigation into Cancer and Nutrition
(EPIC), a large cohort of individuals (over 340,000
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participants over 40 years of age and free of known diabetes at
baseline), followed for 10 years to determine the potential for
these markers to identify those at risk of diabetes [4]. For those
with GADA initially, there was indeed an increased risk that
diabetes would develop during follow-up (HR 1.78 for
GADA positive vs GADA negative). Moreover, the GRS for
type 1 diabetes, but not for type 2 diabetes, was associated
with GADA in incident cases (OR 1.97) (Fig. 2). The GRS
was calculated by multiplying the number of disease risk-
increasing gene alleles by the natural log of OR at each locus,
then summing these ORs for each individual. This risk for
developing diabetes in the EPIC cohort was further increased
to 3.2 by combining GADA positivity with the top tertile of
type 1 diabetes risk according to the GRS (Fig. 2). The
authors, in concluding that incident adult-onset diabetes has
an element of autoimmunity, proposed that the present sub-
classification of diabetes in adulthood should be re-evaluated.
In one sense, we could have anticipated these results. GADA
are known to appear largely within the first decade of life and
predict diabetes in children [5]. However, there have only been a
couple of previous similar prospective studies reporting that
GADA predicted adult-onset diabetes. In the Botnia Study,
GADA (vs no GADA) predicted non-insulin-requiring diabetes
(HR4.9) [6], while in theNord-TrøndelagHealth Study (HUNT),
even evanescent GADA predicted diabetes and these diabetes
patients tended to be younger, with lower C-peptide and higher
HbA1c [7, 8]. As illustrated by this present large study fromEPIC,
the percentagewith GADAwas small, and so the percentage with
GADAwho developed diabetes was small. It seems reasonable to
conclude from these studies that autoimmunity does not play a
major role in the development of adult-onset diabetes among
older adults. Certainly, in population-based studies of adults with
diabetes the frequency of GADA is low, as with this present
European study, while in clinic-based studies, that GADA
frequency tends to be 5–10%, whether in China or Europe [4,
9–11]. Prospective data fromHUNTindicated that incident diabe-
tes cases, who were overweight with a family history of diabetes
plus GADA positivity, as compared with GADA negative cases,
had an OR for diabetes risk of 7.5. By implication, GADA posi-
tivity in the general population identifies a small number at risk of
late adult-onset autoimmune diseases, that is thyroid autoimmu-
nity and diabetes [12]. For diabetes this risk is higher in over-
weight individuals with both a family history of diabetes and high
GRS for type 1 diabetes.
Disease identity and uncertainty
At the heart of this discussion is the issue of disease identity.
Few common diseases are clinically homogeneous; most show
a continuum of clinical changes. Autoimmune diseases are no
exception. Type 1 diabetes is also a heterogeneous condition
with diverse immunogenetic characteristics and clinical
outcomes [2]. This clinical and immunogenetic heterogeneity
extends from childhood-onset autoimmune diabetes into adult-
onset autoimmune diabetes, including people presenting who
do not need insulin therapy [3]. It used to be argued that non-
insulin-requiring adult-onset autoimmune diabetes either did
not exist or was classic type 1 diabetes caught fleetingly in
progression before insulin treatment was required, which would
contrast with the clinical spectrum in Hashimoto’s thyroiditis.
This argument was based on the specificity of the GADA assay
when applied to a general population; in which case a
substantial fraction of GADA positive cases would be false
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Fig. 2 HRs for incident diabetes comparing GADA+ with GADA– cases
within categories of tertiles of BMI and type 1 diabetes mellitus GRS
(T1DMGRS). The plot shows the HR for incident diabetes comparing
GADA+ with GADA–. High HR has been associated with low BMI
(<25 kg/m2); the opposite trend is seen with a high HR for values shown
for T1DMGRS. This shows that GADA+ cases tend to be both genetically
and phenotypically closer to type 1 diabetes than type 2 diabetes. Data
from Rolandsson et al [4]
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Fig. 1 Prevalence of detectable C-peptide by age at diabetes onset and
disease duration (in years). The plot shows the prevalence of detectable
C-peptide by age at onset and duration (years) of the disease. The prev-
alence of C-peptide was 19% in those who were <15 years old at disease
onset and with a disease duration of ≥15 years vs 72% for those whowere
>35 years old at disease onset, with a disease duration of <15 yeasrs. The
diffrence in detectable C-peptide both at baseline and years after diagno-
sis between younger patients (<15 years old) and older patients (>35 years
old) is clear since differences in persistent C-peptide relate to disease age
at onset and duration, especially the former. Data from Mckeigue et al
[21]
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positives. But the argument does not extend to positive predic-
tive values, which can be altered by reconfiguring cut-off points
in specific cohorts, enriching the cohort for clinical features
such as adult-onset diabetes, even altering the assay itself [10,
13]. Nor would it explain the predominance of GADA in all
adult-onset diabetes cohorts when other diabetes-associated auto-
antibodies can be detected, but at far lower frequency, or the
marked drop inGADApositivity with increasing age at diagnosis
in adults [14]. Nevertheless, there will be a false-positive rate,
even with the state-of-the-art GADA assay employed by
Rolandsson et al [4], plus an unquantified, likely low, false-
negative rate. GADA can be transient and, while invariably
predominant, do consistently underestimate the percentage of
diabetes cases with diabetes-associated autoantibodies e.g. in a
clinic-based adult diabetes cohort, diabetes-associated autoanti-
bodies other than GADA detected an additional 7.3% of autoim-
mune cases [9, 10]. By implication, there will be a small number
of additional individuals with other diabetes-associated autoanti-
bodies that were not assayed.
Disease risk, scale and certainty
To support the argument that this cohort of adult-onset autoim-
mune diabetes cases have type 1 diabetes they should have the
type 1 diabetes-associated genetic risk including histocompatibil-
ity antigen (HLA)-associated risk.Major studies fromEurope and
China have shown just that [15, 16]. A large European cohort of
individuals with LADA who were not treated with insulin at
diagnosis showed four genetic signals that achieved genome-
wide significance at established type 1 diabetes risk loci (HLA,
PTPN22, INS and SH2B3) [16]. Indeed, these same four loci were
identified in amajor Chinese study of individuals with adult-onset
type 1 diabetes whowere treatedwith insulin from diagnosis [15].
Despite strong genetic correlations across the whole age range,
childhood-onset type 1 diabetes shows a greater genetic load than
adult-onset type 1 diabetes, consistent with higher GRS and
higher disease concordance rates in twins with childhood-onset
diabetes [17]. By implication, a GRS derived from childhood-
onset type 1 diabetes will underestimate the numbers of cases
with type 1 diabetes genetic risk if applied to an adult cohort
[18]. This underestimation, together with the likely reduced sensi-
tivity for GADA using this highly specific GADA assay and the
likely failure to identify all autoimmune cases as only GADA
were tested means that the actual numbers of autoimmune cases
will probably be higher than estimated. That said, attributable risk
in this population of adult-onset diabetes with GADA is very low
at 1.8%, so even a substantial error would have little impact on the
overall risk of autoimmune diabetes in adults aged over 40 years
[4]. However, the risk of GADA-positive cases developing auto-
immune diabetes would likely be much higher in younger adults,
as autoimmune diabetes is more prevalent in this age group than
in older adults.
Rolandsson et al emphasise the importance of scale in their
data and the notion that autoimmune damage could contribute
to the development of adult-onset diabetes, whether defined
clinically as insulin dependent or non-insulin dependent [4].
Certainly, individuals with adult-onset diabetes who have a
high type 1 diabetes GRS and high-titre GADA are at risk of
progressing to insulin dependence [19]. This risk falls as the
GRS falls [20]. C-peptide levels vary across the age range and
with disease duration, even for individuals diagnosed clinical-
ly and immunologically with type 1 diabetes (Fig. 1) [21].
Older GADA-positive patients, as studied here, with moderate
GRS for type 1 diabetes may clinically resemble patients with
type 2 diabetes in that they could have substantial C-peptide.
A prospective study of C-peptide in older low-titre GADA-
positive Chinese patients (vs high titre) revealed a natural
history indistinguishable from type 2 diabetes over a number
of years [22]. In a large Chinese population-based adult
cohort, ascertained from a notably younger age than in the
present study (i.e. over 20 years), the standardised prevalence
rate of autoimmune diabetes was 6.0% in adults with diabetes
who did not initially require insulin, which corresponds to six
million adults in China with a form of autoimmune diabetes
that is initially non-insulin requiring [9].
Allostasis and tipping points
As insulin secretory capacity is compromised, perhaps by an
autoimmune process, so pathways that maintain glucose
homeostasis and glucose disposition should adjust the levels
of insulin secretion to insulin sensitivity. Allostasis, the ability
to adapt to maintain glucose homeostasis, must be compro-
mised for this homeostasis to be lost with ensuing
dysglycaemia. Taken together, the present data can be viewed
from a dual perspective. On one hand, elements of type 2
diabetes might have an autoimmune basis and from that
perspective the authors call for a re-evaluation of the present
sub-classification of diabetes in adulthood. The problem with
type 2 diabetes is that it lacks a biomarker and is effectively a
diagnosis of exclusion [2, 3]. Furthermore, the GRS for type 2
diabetes is in general very low and many thousands of patients
need to be studied to define differences from a ‘normal’ popu-
lation. Quite what constitutes a ‘normal’ population is another
matter, given the widespread predisposition to dysglycaemia
with age. If these GADA-positive autoimmune cases have a
form of type 2 diabetes, then they would be expected to have
an increased BMI and waist hip ratio, whereas the converse is
true (Fig. 2) [4]. From another perspective, the data could be
seen to validate the hypothesis that autoimmune diabetes is a
spectrum ranging from childhood-onset type 1 diabetes to
adult-onset non-insulin-dependent diabetes masquerading as
type 2 diabetes [2]. Certainly, the higher GRS for type 1 diabe-
tes and leaner habitus of the GADA-positive individuals is
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consistent with this proposal (Fig. 2) [4]. Either way, the argu-
ment is not futile as there is clinical utility in the identification
of autoimmune diabetes. Such patients tend to have a more
dynamic clinical history requiring more frequent clinical
review. In addition, they should probably not be treated with
sulfonylureas, they should be investigated for other forms of
autoimmunity and they are at par t icular r isk of
hyperglycaemia and progression to insulin therapy [2, 23–25].
In short, the autoimmune process is associated with diabe-
tes, but that risk is a continuum, just as glucose and glucose
disposition, insulin secretion and insulin sensitivity represent
continua. For the physician, biomarkers are merely guides to
management but will surely help a more nuanced approach to
the patient sitting in front of you.
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